Inmune Bio (DE:0Y2)
NASDAQ:0Y2
0Y2 Stock Chart & Stats
€1.59
-€0.25(-4.63%)
At close: 4:00 PM EST
€1.59
-€0.25(-4.63%)
Day’s Range― - ―
52-Week Range€1.21 - €11.80
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€28.57M
Enterprise Value€17.64M
Total Cash (Recent Filing)€21.36M
Total Debt (Recent Filing)€1.51M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Aug 05, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.69
Shares Outstanding26,585,258
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.76
Price to Sales (P/S)829.46
P/FCF Ratio-1.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.89Price Target Upside333.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.61
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA Fast Track For XProFast Track designation creates durable regulatory engagement and potential expedited review pathways. That sustained interaction supports a biomarker‑driven Phase2b/3 registrational program, improving chances for efficient trial design, clearer FDA dialogue, and a stronger competitive positioning over the coming development cycle.
Phase 2 MRI Imaging Shows Target EngagementRobust imaging and biomarker signals provide biological proof‑of‑mechanism and reduce scientific risk. Durable target engagement evidence supports precision‑medicine enrollment, increases likelihood of persuasive registrational endpoints, and strengthens the development and partnership case over multiple trial phases.
Manufacturing Validation And Secured Cord SupplyProcess validation runs plus a long‑term supply agreement materially lower CMC and supplier risk. This durable operational readiness improves credibility for MAA/future regulatory filings and commercialization planning, making scale‑up and launch execution more feasible if approvals are obtained.
Bears Say
Pre‑commercial; Zero TTM Revenue And Large LossesWith no recurring revenue and substantial trailing losses, the company lacks internal cash generation. This structural unprofitability means long‑term sustainability depends on external capital or partnerships, constraining strategic optionality and increasing investor dilution risk if financing is required to reach commercialization.
Limited Cash Runway; Near‑term Financing RiskA funding horizon only into Q1 2027 creates a durable execution risk: management may need to secure capital within ~12 months. Financing events can dilute shareholders, distract management, or force strategic concessions, and any timing mismatch could delay regulatory submissions or completion of validation runs.
Large R&D Cut May Slow Development MomentumA sustained >50% reduction in R&D investment can meaningfully slow trial execution, data generation, and program advancement. Reduced internal spend increases timeline risk for registrational plans, may weaken competitive differentiation, and could reduce partner interest during critical pre‑approval development stages.
Inmune Bio News
0Y2 FAQ
What was Inmune Bio’s price range in the past 12 months?
Inmune Bio lowest stock price was €1.21 and its highest was €11.80 in the past 12 months.
What is Inmune Bio’s market cap?
Inmune Bio’s market cap is €28.57M.
When is Inmune Bio’s upcoming earnings report date?
Inmune Bio’s upcoming earnings report date is Aug 05, 2026 which is in 56 days.
How were Inmune Bio’s earnings last quarter?
Inmune Bio released its earnings results on May 07, 2026. The company reported -€0.172 earnings per share for the quarter, beating the consensus estimate of -€0.21 by €0.039.
Is Inmune Bio overvalued?
According to Wall Street analysts Inmune Bio’s price is currently Undervalued.
Does Inmune Bio pay dividends?
Inmune Bio does not currently pay dividends.
What is Inmune Bio’s EPS estimate?
Inmune Bio’s EPS estimate is -0.16.
How many shares outstanding does Inmune Bio have?
Inmune Bio has 26,585,258 shares outstanding.
What happened to Inmune Bio’s price movement after its last earnings report?
Inmune Bio reported an EPS of -€0.172 in its last earnings report, beating expectations of -€0.21. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Inmune Bio?
Currently, no hedge funds are holding shares in DE:0Y2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inmune Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€6.89 (333.16% Upside)
€6.89 (333.16% Upside)
Blogger Sentiment
Bullish
DE:0Y2 Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.72%
12-Months-Change
Fundamentals
Return on Equity
-170.86%
Trailing 12-Months
Asset Growth
-31.70%
Trailing 12-Months
Company Description
Inmune Bio
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
0Y2 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful, tangible progress toward a key inflection point: CORDStrom advanced through regulatory planning (PIP approval), manufacturing validation runs began, and a long-term supply agreement was secured — all supportive milestones. XPro imaging work and partnership exploration were also positive. Offsetting these positives are schedule/regulatory timing shifts, a materially limited cash runway (funding through Q1 2027), and a large year-over-year reduction in R&D spend that could indicate slower near-term investment. Overall the call shows constructive execution on regulatory and manufacturing fronts but meaningful financing and execution risks remain.View all DE:0Y2 earnings summaries0Y2 Stock 12 Month Forecast
Average Price Target
€6.89
▲(333.16% Upside)
Technical Analysis
Veru
―
Karyopharm Therapeutics
―
Cue Biopharma
―
Celularity
―
Jupiter Neurosciences, Inc.
―
Options Prices
Currently, No data available
---